And if you paid attention (at times I have been too poor to
And if you paid attention (at times I have been too poor to pay attention)
he said...."that is OUR position".
Our, as in several or many.
meaning "conglomerate" not just UNVC.
Maybe meaning...Amazon, EagleForce, BioRemedies, Time Organization, HRI, PPS..
It's a bureaucratic proceedure, sometimes affected by people's daily life schedules, current health status, and many other things.
I know one thing, I know more people that have contracted Covid in the last several weeks than I have heard of in months. There are some sick ass people out there right now and a lot of people afraid to be around them or even show up to work. Not making any excuses, because I haven't stopped working since this whole thing started.But not everyone is me.
I think Doc might have thought we would get the Pink Current status instead of the Yield sign. Who knows.
Holding tight to my shares, I have to make the most of them!!!!
10
1
Univec Conglomerate Inc (UNVC) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
CaliberMRI: Pioneers Shaping the Future of MRI Hot off the press, folks—CaliberMRI, known for setting the bar high in MRI standardization, has unleashed a new beast on the scene. Enter Model 340, a preclinical quantitative MRI phantom, ready to knock the socks off high-field systems. They’re talking 4.7T, 7T, and a jaw-dropping 9.4T compatibility here. This isn't just...
Continue Reading
If you've ever wondered about the intersection of military discipline and entrepreneurial spirit, LINE-X is handing veterans the keys, quite literally. With a nod to leathernecks and GIs, they're slashing their franchise fee by 25% for U.S. veterans aiming to trade sergeants' stripes for business clout. Franchising for Veterans: A Tailored Offer So, the word on the street...
Continue Reading
A Nutty Approach to Diabetes Prevention Who would've thought peanuts could pack such a punch against diabetes? Amid the usual suspects of healthy foods, it's these humble legumes that are making headlines. The Peanut Institute, backed by fresh research, is shining a spotlight on their potential role in preventing type 2 diabetes, a disease that's affecting roughly 40...
Continue Reading
VA Loans: Unused Potential Sits at $41 Billion Are you telling me we're leaving $41 billion just sitting on the table in the form of untapped VA loans? That's the figure staring us in the face according to Veterans United's latest analysis. It's not just about numbers; it's a head-scratcher given the growing VA loan market share, which hit 10% last year. Where's the...
Continue Reading
Sometimes the anticipation of a financial report presentation feels akin to waiting for a storm to pass or the sun to finally break through after what seems like endless rain. That’s the kind of vibe we're getting from Sectra's upcoming six-month report presentation. Slated for November 25, President Torbjörn Kronander and CFO Jessica Holmquist will be stepping up to...
Continue Reading
AI's Surge in the Boating World Well, look who’s riding the AI wave—it's our old friends at Boat Trader and YachtWorld, leaving the competition coughing in their slipstream. Similarweb data throws some cold, hard fish onto the deck, showing these two raking in over 17 times the AI-referred traffic compared to their closest peers. If you’re sniffing around for where...
Continue Reading
Launching into Vitiligo Treatment Trials I'll tell you, the biotech world isn't for the faint-hearted, especially when you're juggling hefty terms like 'TYK2/JAK1'. But here we are, watching Accro Bioscience and Fosun Pharma dive headlong into the vitiligo space with this Phase II/III trial of AC-201. They've bagged the IND clearance, and now the first patient is in the...
Continue Reading
Innovative Moves in Bioprocessing Let's get one thing clear right off the bat—CPC Biotech, part of Dover (NYSE: DOV), just sent a signal loud and clear with their new Quattroflow HTX all-in-one pump drive. With a slick touchscreen, flexible control options, and self-touting accuracy, this thing sounds like it's set to change the game for biopharmaceutical processing....
Continue Reading
Transforming AI from Cost to Profit Alright folks, we all know AI's the flashy tool everyone's jumping on like it's the latest tech bandwagon. But here’s the raw deal: most of these shiny AI investments ain't paying back a damn thing. Enter the AI Adoption Institute (AiAi)—a new player in Denver aiming to salvage this mess and make AI about actual returns. Peering...
Continue Reading
Another Feather in Bramshill's Cap They've done it again, folks. The Bramshill Multi-Strategy Income Fund has just snagged the 40 Act Fund of the Year award at the 2026 Hedge Fund Performance Awards. This ain't just another plaque for the wall; it's a nod to some serious heavy lifting by the folks handling this beast of a portfolio. The award, dished out by With...
Continue Reading
Top 5 Most Recently Viewed Articles
Twilio Inc Fourth Quarter Overview Twilio Inc reported notable financial results for the fourth quarter, capturing the attention of several analysts within the market. The company’s performance has sparked diverse reactions, particularly regarding its future guidance and the evolving role of artificial intelligence within its operations. Market Response to Q4 Earnings...
Continue Reading
FHLBank Indianapolis Declares Second Quarter Dividends FHLBank Indianapolis recently announced its second quarter dividends for 2025, detailing robust financial strategies and growth, as reflected in the declared dividends on Class B-2 activity-based capital stock and Class B-1 non-activity-based stock. These dividends have been set at annualized rates of 9.50% and 4.50%,...
Continue Reading
Revolutionizing Alzheimer's Detection with Neurogen Biomarking Neurogen Biomarking is making significant strides in the healthcare landscape by introducing a pioneering blood test aimed at the early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). This innovative approach leverages advanced biomarker technology developed by Quanterix Corporation,...
Continue Reading
Revolutionizing Industries with the K2 Bumblebee Shanghai Kepler Robotics Co., Ltd has excitedly announced the commencement of mass production of its K2 "Bumblebee" model, confirming that the world's first commercially available hybrid-architecture humanoid robot is now shipping to eager customers. Milestone in Humanoid Robotics This significant development not only marks...
Continue Reading
Positive Interim Data from Syntara's Clinical Trials Syntara Limited, known for its innovative approach in drug development, has unveiled promising interim data concerning its ongoing Phase 2 study of SNT-5505. This clinical trial focuses on myelofibrosis, a complex bone marrow disorder that often leads to severe health complications. Details of the Clinical Trial The...
Continue Reading